Neurogene, Inc.

XNASHealth care

Last traded price · USD

$27.58

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.58
Volume: —
Day's high: —
Day's low: —

In brief

Neurogene, Inc. is a health care company listed on Nasdaq, valued at about $552M.
Its shares closed at $27.58 on 4 Nov 2026, down 13.3% over the past year.
From India you can buy NGNE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Neurogene, Inc. (NGNE) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NGNE share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NGNE options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.4% (SPY −1.6%, XLV +13.5%). 3 months: −23.3% (SPY −0.4%, XLV +15.5%). 1 year: −13.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NGNE, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $27.58 was 8.0% below its 50-day average ($29.97) and 1.3% below its 200-day average ($27.96). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed above the 200-day on 28 Apr 2026, 132 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.4 days to cover short interest
5.1M shares were sold short at the 15 Oct 2026 settlement, 25.5% of the 20.0M shares outstanding; covering them would take 14.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
42% of the way up its 52-week range
Closed at $27.58 on 4 Nov 2026: 36.8% below the 52-week high of $43.66 (9 Jul 2026) and 73.1% above the low of $15.93 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.4%

6 months−14.7%

1 year−13.3%

5 years—

Newswire

About

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Website

Notable moves

November 18, 2024
−42.58%
November 12, 2024
−44.08%
November 4, 2024
+43.26%

Newswire

About

Website

Notable moves

November 18, 2024
−42.58%
November 12, 2024
−44.08%
November 4, 2024
+43.26%

Neurogene, Inc.

XNASHealth care

Last traded price · USD

$27.58

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.58
Volume: —
Day's high: —
Day's low: —

In brief

Neurogene, Inc. is a health care company listed on Nasdaq, valued at about $552M.
Its shares closed at $27.58 on 4 Nov 2026, down 13.3% over the past year.
From India you can buy NGNE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Neurogene, Inc. (NGNE) shares from India?

Do I need the price of a whole NGNE share to invest?

How much can I invest in US stocks in a year?

Can I trade NGNE options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.4% (SPY −1.6%, XLV +13.5%). 3 months: −23.3% (SPY −0.4%, XLV +15.5%). 1 year: −13.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NGNE, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $27.58 was 8.0% below its 50-day average ($29.97) and 1.3% below its 200-day average ($27.96). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed above the 200-day on 28 Apr 2026, 132 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.4 days to cover short interest
5.1M shares were sold short at the 15 Oct 2026 settlement, 25.5% of the 20.0M shares outstanding; covering them would take 14.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
42% of the way up its 52-week range
Closed at $27.58 on 4 Nov 2026: 36.8% below the 52-week high of $43.66 (9 Jul 2026) and 73.1% above the low of $15.93 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.4%

6 months−14.7%

1 year−13.3%

5 years—

Newswire

About

Website

Notable moves

November 18, 2024
−42.58%
November 12, 2024
−44.08%
November 4, 2024
+43.26%

Newswire

About

Website

Notable moves

November 18, 2024
−42.58%
November 12, 2024
−44.08%
November 4, 2024
+43.26%

Neurogene, Inc.

Neurogene, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

14.4 days to cover short interest

42% of the way up its 52-week range

Neurogene, Inc.

Neurogene, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

14.4 days to cover short interest

42% of the way up its 52-week range